Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Low immune response to hepatitis B vaccine among children in Dakar, Senegal
PLoS ONE, Volume 7, No. 5, Article e38153, Year 2012
Notification
URL copied to clipboard!
Description
HBV vaccine was introduced into the Expanded Programme on Immunization (EPI) in Senegal and Cameroon in 2005. We conducted a cross-sectional study in both countries to assess the HBV immune protection among children. All consecutive children under 4 years old, hospitalized for any reason between May 2009 and May 2010, with an immunisation card and a complete HBV vaccination, were tested for anti-HBs and anti-HBc. A total of 242 anti-HBc-negative children (128 in Cameroon and 114 in Senegal) were considered in the analysis. The prevalence of children with anti-HBs ≥10 IU/L was higher in Cameroon with 92% (95% CI: 87%-97%) compared to Senegal with 58% (95% CI: 49%-67%), (p<0.001). The response to vaccination in Senegal was lower in 2006-2007 (43%) than in 2008-2009 (65%), (p = 0.028). Our results, although not based on a representative sample of Senegalese or Cameroonian child populations, reveal a significant problem in vaccine response in Senegal. This response problem extends well beyond hepatitis B: the same children who have not developed an immune response to the HBV vaccine are also at risk for diphtheria, tetanus, pertussis (DTwP) and Haemophilus influenzae type b (Hib). Field biological monitoring should be carried out regularly in resource-poor countries to check quality of the vaccine administered. © 2012 Rey-Cuille et al.
Authors & Co-Authors
Rey-Cuille, Marie Anne
France, Paris
Institut Pasteur, Paris
France, Paris
Insb - Institut Des Sciences Biologiques
Seck, Abdoulaye
Senegal, Dakar
Institut Pasteur de Dakar
Njouom, Richard
Cameroon, Yaounde
Centre Pasteur du Cameroun
Chartier, Loïc
France, Paris
Institut Pasteur, Paris
Sow, Housseyn Dembel
Senegal, Dakar
Hopital D'enfants Albert-royer Dakar
MamadouBa,
Senegal, Dakar
Hopital D'enfants Albert-royer Dakar
Kâ, Amadou Sidy
Senegal, Dakar
Hopital Principal de Dakar
Njankouo, Mohamadou Ripa
Cameroon, Yaounde
Centre Pasteur du Cameroun
Rousset, Dominique
Cameroon, Yaounde
Centre Pasteur du Cameroun
Giles-Vernick, Tamara
France, Paris
Institut Pasteur, Paris
Unal, Guillemette
France, Paris
Institut Pasteur, Paris
Sire, Jean Marie
Senegal, Dakar
Institut Pasteur de Dakar
France, Paris
Hôpital Saint-louis
Garin, Benoît
Senegal, Dakar
Institut Pasteur de Dakar
Simon, Franćois
France, Paris
Hôpital Saint-louis
Vray, Muriel M.
France, Paris
Institut Pasteur, Paris
France, Paris
Inserm
Statistics
Citations: 38
Authors: 15
Affiliations: 8
Identifiers
Doi:
10.1371/journal.pone.0038153
e-ISSN:
19326203
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Cross Sectional Study
Study Approach
Quantitative
Study Locations
Cameroon
Senegal